Abstract: The present disclosure includes ingestible devices. In some examples, an ingestible device is presented that includes a framework, a control device secured to the framework, and a partial power source. The partial power source may include a first digestible material secured to the framework and electrically coupled to the control device, and a second digestible material electrically isolated from and dissimilar to the first digestible material, electrically coupled to the control device, and secured to the framework. The partial power source may be configured to provide power to the control device when the first and second digestible materials come in contact with a conductive fluid. The control device, after being provided power by the first and second digestible materials, may be configured to alter conductance between the first and second digestible materials to produce a current signature through the conductive fluid that is detectable by a receiver.

Abstract: An anticancer compound is disclosed which is represented by the formula ##STR1## wherein one of R.sup.1 and R.sup.2 is a phenyl-lower alkyl optionally having a substituent, phenyl-lower alkenyl or naphthyl-lower alkyl, the other of R.sup.1 and R.sup.2 is hydrogen or acyl, and R.sup.3 is hydrogen, acyl or tetrahydrofuranyl, or represented by the formula ##STR2## wherein R.sup.x is an optionally substituted pyridyl, Y is arylene and .alpha. is a known 5-fluorouracil derivative residue which can be converted to 5-fluorouracil in vivo and which is linked to the carbonyl by an ester or amide linkage.